(3S,8S,9S,10R,13R,14S,17R)-17-((2R,5S)-5-Cyclopropyl-5-hydroxyhexan-2-yl)-3,10,13-trimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol

ID: ALA5200422

Chembl Id: CHEMBL5200422

PubChem CID: 86303931

Max Phase: Preclinical

Molecular Formula: C29H48O2

Molecular Weight: 428.70

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@H](CC[C@](C)(O)C1CC1)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C

Standard InChI:  InChI=1S/C29H48O2/c1-19(12-15-29(5,31)20-6-7-20)23-10-11-24-22-9-8-21-18-26(2,30)16-17-27(21,3)25(22)13-14-28(23,24)4/h8,19-20,22-25,30-31H,6-7,9-18H2,1-5H3/t19-,22+,23-,24+,25+,26+,27+,28-,29+/m1/s1

Standard InChI Key:  FEGRCLVMYKTTDC-FBIXSMBYSA-N

Associated Targets(Human)

GRIN1 Tclin Glutamate NMDA receptor; GRIN1/GRIN2A (719 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GRIN1 Tclin Glutamate NMDA receptor; GRIN1/GRIN2B (726 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 428.70Molecular Weight (Monoisotopic): 428.3654AlogP: 6.89#Rotatable Bonds: 5
Polar Surface Area: 40.46Molecular Species: NEUTRALHBA: 2HBD: 2
#RO5 Violations: 1HBA (Lipinski): 2HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: CX LogP: 5.90CX LogD: 5.90
Aromatic Rings: Heavy Atoms: 31QED Weighted: 0.47Np Likeness Score: 2.44

References

1. Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, Dai J, Doherty JJ, Harrison BL, Hoffmann EC, Kazdoba TM, Lanzetta D, Lewis M, Quirk MC, Robichaud AJ..  (2022)  SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment.,  65  (13.0): [PMID:35785990] [10.1021/acs.jmedchem.2c00313]

Source